ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Authors:
- Marileila Varella-GarciaMVMarileila Varella-Garcia
- D Ross CamidgeDCD Ross Camidge
- 1 December 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (12) , 1450-1454
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Pathobiology of ALK+ anaplastic large-cell lymphomaBlood, 2007
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- A census of human cancer genesNature Reviews Cancer, 2004